===Novo Nordisk (NVO) launches bidding war with Pfizer (PFE) for US obesity biotech Metsera (MTSR)

Novo Nordisk makes $6.5 billion acquisition offer for Metsera (MTSR), declared superior to Pfizer's prior bid by Metsera's board and potentially triggering a bidding war for the obesity drug developer.

• Pfizer has 4 days to respond to this bid
• Mon 11/3: Pfizer files second lawsuit to block Novo Nordisk's Metsera acquisition with counter bid deadline tomorrow, and is set to report earnings where management will address key strategic questions.

Oct 30, 2025 : Pfizer Addresses Proposal for Metsera

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk. The proposal is illusory and cannot qualify as a superior proposal under Pfizer’s agreement with Metsera, and Pfizer is prepared to pursue all legal avenues to enforce its rights under its agreement.

***

Metsera (MTSR) shares jumped nearly 19% premarket on Thursday after Bloomberg reported that Danish drugmaker Novo Nordisk (NVO) has made a higher offer for the obesity startup, aiming to outmatch Pfizer’s (PFE) previously agreed deal and strengthen its dominance in the fast-growing weight-loss drug market.

Novo, which had made an earlier offer before Metsera’s $4.9 billion agreement with Pfizer, has now returned with an improved proposal in both value and structure, the report said, citing sources. The companies are in advanced discussions, and a potential agreement could be reached as soon as Thursday, though no final decision has been made.

Pfizer’s deal, announced in September, included $47.50 per share upfront and up to $22.50 per share in milestone payments. A Metsera deal would deal a setback to Pfizer (PFE), which is struggling with declining Covid vaccine sales and looming patent expirations after its own obesity pill failed due to safety issues.

Novo Nordisk (NVO), though leading in weight loss, is also under pressure to develop next-generation treatments after its CagriSema drug underperformed, as it seeks to stay ahead of Eli Lilly (LLY).

Metsera’s (MTSR) shares have nearly tripled this year to $52.21, valuing the company at about $5.5 billion. Pfizer (PFE) shares were little changed, while Novo Nordisk (NVO) slipped 1.5% in Copenhagen.

The firm is developing next-generation obesity treatments, including a long-acting amylin analogue that could require less frequent dosing than the market-leading drugs from Novo Nordisk’s (NVO) and Eli Lilly’s (LLY). Amylin-based drugs are seen as a gentler alternative to GLP-1 treatments like Wegovy and Zepbound, which often cause nausea and vomiting.

Grupo Aeroméxico's IPO

Overview of Grupo Aeroméxico's IPO

Grupo Aeroméxico, S.A.B. de C.V., Mexico's flagship airline and the country's only full-service carrier offering long-haul wide-body flights, is preparing for a dual listing on the New York Stock Exchange (NYSE) and the Mexican Stock Exchange (Bolsa Mexicana de Valores, BMV). This marks the airline's return to public markets after delisting in 2022 following its emergence from Chapter 11 bankruptcy protection amid the COVID-19 crisis. The IPO process began with an initial SEC filing in May 2024, followed by a registration statement in September 2025, and terms were unveiled in mid-October 2025.
The offering is backed by major investors, including Apollo Global Management (a key shareholder post-restructuring) and Delta Air Lines (which holds a 20% stake and has agreed to a four-year lockup on its shares). Aeroméxico, founded in 1934 and a co-founder of the SkyTeam alliance, operates flights to every major Mexican city and 52 international destinations across 22 countries, with a focus on high-demand leisure routes like Cancun and Puerto Vallarta.Key IPO Details

Aspect	Details
Ticker Symbol	AERO (NYSE for American Depositary Shares/ADS; BMV for ordinary shares)
Shares Offered	- U.S.: 11.73 million ADS (each representing 10 ordinary shares) - Company: 7.39 million ADS (primary) - Selling shareholders: 4.33 million ADS (secondary) - Mexico: 7 million new shares + 20.46 million from selling shareholders
Price Range	$18–$20 per ADS
Expected Proceeds	- U.S. IPO: $223–$234 million (midpoint: $222.8 million) - Total with private placement: Up to $314 million (includes $25 million from PAR Investment Partners at a 5% discount to IPO price)
Valuation Target	Up to $2.92 billion (fully diluted)
Underwriters	Joint book-runners: Barclays, Morgan Stanley, J.P. Morgan, Evercore ISI Other book-runners: Apollo Global Securities, Citigroup, Deutsche Bank Securities, Goldman Sachs, BNP Paribas, BTG Pactual, Santander
Expected Timeline	- Roadshow: Late October 2025 - Pricing: Potentially week of October 28, 2025 - Trading start: Shortly after pricing (exact date TBD)
Use of Proceeds	Primarily for general corporate purposes, including debt repayment and fleet expansion; secondary shares benefit selling shareholders

Financial Highlights (Trailing 12 Months Ended June 30, 2025)Aeroméxico reported strong post-restructuring performance, driven by robust demand in the Mexico-U.S. transborder market and leisure travel:

• Revenue: $5.42 billion
• Net Income: $360.8 million
• Market Share: 36.3% of total passengers to/from/within Mexico (per Mexico's Federal Aviation Agency)
• Fleet: Operates ~140 aircraft, with plans for growth in wide-body international routes.

Market Context and RisksThis IPO follows LATAM Airlines' $456 million NYSE relisting in July 2024, signaling recovery in Latin American aviation. Mexico's 2.8% GDP growth in 2025 and rising tourism support demand, but investors should note risks like fuel price volatility, geopolitical tensions affecting travel, and currency fluctuations (peso vs. USD). The dual U.S.-Mexico structure aims to attract global capital while relisting locally.

Arcutis Biotherapeutics (ARQT) reported earnings on Tue 28 Oct 25 (b/o)

• Arcutis Biotherapeutics reports Q3 2025 results with $99.2M in ZORYVE sales, $7.4M net income, issues 2026 revenue guidance, and outlines growth strategy at Investor Day presentation.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. 

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 342
• Incorporated in 2016 
• Headquartered in Westlake Village, California.
• https://www.arcutis.com

IPO: Jan 31, 2020

Ticker: ARQT

 

 

 

 

Arcutis Biotherapeutics announces third quarter 2025 results; provides initial 2026 full year net product sales guidance of $455-$470 mln

WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today outlined its strategy to achieve sustainable growth and reported financial results for the quarter ended September 30, 2025.

World's most valuable private companies

1. OpenAI: $500 billion

2. SpaceX: $400 billion

3. ByteDance: $330 billion

 4. Anthropic: $183 billion

 5. xAI: $113 billion

 6. Databricks: $100 billion

 7. Stripe: $92 billion

 8. Revolut: $75 billion

 9. Shein: $66 billion

Kodiak AI (KDK) began trading on the Nasdaq on Thur 25 Sept 25

Kodiak Robotics, Inc. builds and operates self-driving trucks. The company delivers freight for its customers between Dallas-Fort Worth and Houston. It offers solutions in the areas of updating automated drivers, a network of transfer points facilitates, and fleet management tools. 

• Sector: Industrials
• Industry: Farm & Heavy Construction Machinery
• Founder and CEO Don Burnette
• Incorporated in 2018 
• HQ based in Mountain View, California, with an operations center in Lancaster, Texas
• https://kodiak.ai

Kodiak AI (KDK) began publicly trading on the Nasdaq via a SPAC deal (Special Purpose Acquisition Company). Autonomous trucking startup Kodiak Robotics merged with Ares Acquisition Corp. II (AACT) to form the new company.

 

2 Oct 25 

 

Kodiak was founded in 2018 by industry veteran, Don Burnette, with a vision of becoming the trusted world leader in autonomous ground transportation dedicated to commercializing driverless trucking at scale. In 2024, we believe Kodiak became the first company to announce delivery of a driverless trucking product to a customer.
 

===Leap Therapeutics (LPTX) : $58.9 million private placement led by Winklevoss Capital

Oct 06: Leap Therapeutics announces $58.9 million private placement led by Winklevoss Capital and files SEC disclosure, initiating a digital asset treasury strategy.

 

Confluent (CFLT) : 4-year performance

Confluent, Inc. engages in creating a data infrastructure platform focused on data in motion. The firm provides application architecture engagement, multi data center, security and upgrade engagement, and Amazon web services cloud deployment services. Its products include Confluent Cloud, Confluent Platform, WarpStream BYOC, Connectors, Flink, Stream Governance, and Confluent Hub. 

The company was formerly known as Infinitem, Inc. and changed its name to Confluent, Inc. in September 2014. 

• Founded by Edward Jay Kreps, Neha Narkhede, and Jun Rao in 2014
• Headquartered in Mountain View, California
• Sector: Technology
• Industry: Software - Infrastructure
• Full Time Employees: 3,060
• Website:  confluent.io
• Ticker: CFLT

 

NusaTrip (NUTR) : 2-month performance

Update Aug 3, 2016:  Nasdaq says NusaTrip (NUTR) faces delisting on Aug. 12 unless it appeals

• Nasdaq notified NusaTrip that its securities will be delisted from the Nasdaq Stock Market on August 12, 2026 unless the company appeals to a Listing Qualifications Hearings Panel.
• NusaTrip shares will remain halted and unavailable for trading until any appeal is resolved.
• Nasdaq said it is using its authority under IM-5101-4 after the SEC's temporary trading suspension and Nasdaq's October 23, 2025 trading halt.
• If removed from Nasdaq, the securities may become eligible to trade in the over-the-counter market.

***

NusaTrip Incorporated closed its initial public offering on August 18, 2025, raising $15 million by offering 3.75 million shares of common stock at a price of $4.00 per share. 

 

IPO Overview

Listing Date: August 15, 2025 (Nasdaq Capital Market)
Ticker Symbol: NUTR
Shares Offered: 3,750,000
Offer Price: $4.00 per share
Gross Proceeds: $15 million (plus an additional $2.25 million via full exercise of the overallotment option)
Sole Bookrunner: Cathay Securities

 

Company Details & Background

Profile: Headquartered in Jakarta, Indonesia, NusaTrip is an online travel agent (OTA) specializing in the Southeast Asia and Asia-Pacific regions. It was the first Indonesian OTA to gain International Air Transport Association (IATA) accreditation.
Parent/Controlling Shareholder: Spun out and controlled by Society Pass (SOPA).
Use of Proceeds: Expansion into new markets, merger and acquisition initiatives, and general corporate working capital.